NCT00390156View on ClinicalTrials.gov

Imatinib, Bevacizumab, and Cyclophosphamide in Patients With Refractory Metastatic Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

January 31, 2011

Study Completion Date

January 31, 2011

Conditions
Unspecified Adult Solid Tumor
Interventions
BIOLOGICAL

bevacizumab

5 mg/kg

DRUG

cyclophosphamide

Current dose 50 mg

DRUG

imatinib

Current dose 400 mg

Trial Locations (1)

94143-1705

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

University of California, San Francisco

OTHER